Every 424B that VICARIOUS SRGCL INC A (RBOT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RBOT filings page.
Vicarious Surgical Inc. is offering up to $3,000,000 of Class A common stock through an at-the-market program under an existing $100,000,000 shelf registration. The shares will be sold from time to time on the New York Stock Exchange or other U.S. trading markets through H.C. Wainwright & Co. as sales agent or principal, earning a 3.0% commission on gross proceeds. Based on a recent NYSE price of $2.17, this would represent up to 1,382,488 shares, with total Class A shares outstanding potentially rising to 7,845,739, though actual issuance will depend on future trading prices and sale decisions.
The company plans to use any net proceeds for general corporate purposes, including working capital, capital spending, and research and development or clinical trial costs, and may also fund possible acquisitions or strategic investments. Vicarious Surgical is developing a single-port robotic surgical system that has not yet been authorized by the FDA and remains in a pre-commercial, development-focused stage. The company has an NYSE compliance plan in place after previously falling below market capitalization and equity listing thresholds, and warns that investors face significant risks, including dilution and share price volatility.
Vicarious Surgical Inc. is registering for resale up to 2,300,000 shares of Class A common stock issuable from Series A and Series B common warrants held by a single selling stockholder. The company is not offering any shares in this prospectus and will only receive cash if these $5.10 warrants are exercised for cash.
Class A common stock outstanding was 6,126,891 shares as of December 4, 2025, and would be 8,194,273 shares assuming full warrant exercise, illustrating the potential dilution if all warrants are exercised. The selling holder may sell shares over time in public or private transactions at market or negotiated prices.
Vicarious Surgical is developing a next-generation single-port robotic system for soft tissue surgery, which has not yet received FDA authorization. The company completed two controlled builds of its platform in 2025, targets a clinical-ready system by mid-2026 and first-in-human trials in 2027, and is operating under an NYSE compliance plan after previously falling below a $50 million market capitalization standard.
Vicarious Surgical Inc. is offering Class A common stock at $5.10 per share and Pre-Funded Warrants at $5.0999 each, with purchasers reimbursing a placement agent for up to $100,000 of offering expenses. The base offering is 5,305,724 shares and would reach 6,455,724 shares assuming full exercise of the Pre-Funded Warrants. After the offering (assuming no exercise of Pre-Funded Warrants), Class A stock would represent 90.0% of issued share capital and 31.1% of combined voting power; Class B would represent 10.0% of issued share capital and 68.9% of combined voting power.
Reported per-share net tangible book value before the offering is $3.8773, increasing by $0.1026 to an as-adjusted $3.9799, with dilution to new investors of $1.1201. The Pre-Funded Warrants will not be listed, limiting their liquidity. A concurrent private placement includes Series A and Series B Common Warrants to purchase 1,150,000 shares each at an exercise price of $5.10.
Risk disclosures highlight barriers in the surgical robotics market: legacy systems have limited capabilities, are difficult to use, show low utilization, and carry significant capital investment costs—estimated up to $2.0M per system plus 10-20% annual service.